DXCM Dexcom Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$75.37

Market cap

$29.08B

P/E Ratio

31.4

Dividend/share

N/A

EPS

$2.4

Enterprise value

$29.3B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: 52
Relative Profitability: Rel. Profitability: 95

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
The EPS has soared by 78% YoY and by 12% QoQ
Dexcom's net income has soared by 74% YoY and by 11% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.dexcom.com/
Peers: EW WST BDX TNDM

Key stats

What are the main financial stats of DXCM

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
0.16%
1 week
3.44%
1 month
23.27%
1 year
-9.03%
YTD
13.56%
QTD
20.02%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$4.82B
Gross profit
$2.96B
Operating income
$1.03B
Net income
$930.4M
Gross margin
61.5%
Net margin
19.3%
Dexcom's net income has soared by 74% YoY and by 11% from the previous quarter
DXCM's operating income has surged by 63% year-on-year and by 13% since the previous quarter
The net margin has increased by 50% YoY and by 8% from the previous quarter
The operating margin has increased by 40% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does DXCM's price correlate with its fundamentals

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
DXCM P/E details
P/E
31.4
P/B
9.81
P/S
6.02
EV/EBIT
23.98
EV/EBITDA
19.78
EV/Sales
6.08
The EPS has soared by 78% YoY and by 12% QoQ
The stock's price to earnings (P/E) is 67% less than its 5-year quarterly average of 94.0 and 18% less than its last 4 quarters average of 38.5
DXCM's P/B is 44% below its 5-year quarterly average of 17.5 and 2.9% below its last 4 quarters average of 10.1
The company's equity rose by 30% YoY and by 8% QoQ
The stock's price to sales (P/S) is 51% less than its 5-year quarterly average of 12.2
Dexcom's revenue has increased by 16% YoY and by 3.3% from the previous quarter

Efficiency

How efficient is Dexcom business performance
DXCM's return on invested capital has surged by 100% year-on-year and by 14% since the previous quarter
Dexcom's ROA has soared by 65% YoY and by 12% from the previous quarter
The ROS rose by 40% YoY and by 7% QoQ
The ROE is up by 39% year-on-year and by 4.3% since the previous quarter

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 80% higher than its total liabilities
Dexcom's current ratio has increased by 30% YoY and by 3.7% QoQ
The quick ratio has grown by 24% year-on-year and by 5% since the previous quarter
The debt is 55% less than the equity
DXCM's debt to equity has shrunk by 59% YoY and by 8% QoQ
The debt has decreased by 47% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.